Stocks
Black Diamond Therapeutics Financial Statements (BDTX) |
||||||||||
| Black Diamond Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 24.03.2020 | 25.03.2021 | 17.03.2022 | 09.03.2023 | 12.03.2024 | 05.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 4.89 | |||
| Operating Income, bln rub | -8.90 | -69.6 | -126.9 | -92.8 | -86.5 | -81.4 | ||||
| EBITDA, bln rub | ? | -29.3 | -66.7 | -126.7 | -92.3 | -86.0 | -78.4 | |||
| Net profit, bln rub | ? | -41.1 | -65.5 | -123.2 | -84.5 | -82.4 | -73.1 | |||
| OCF, bln rub | ? | -24.7 | -52.1 | -100.1 | -85.1 | -66.7 | -61.2 | |||
| CAPEX, bln rub | ? | 0.021 | 0.142 | 2.71 | 0.192 | 0.033 | 29.5 | |||
| FCF, bln rub | ? | -24.7 | -52.3 | -102.9 | -85.3 | -66.8 | -46.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 29.3 | 69.6 | 126.9 | 92.8 | 86.5 | 81.1 | ||||
| Cost of production, bln rub | 0.047 | 0.600 | 2.22 | 3.24 | 0.437 | 0.344 | ||||
| R&D, bln rub | 21.8 | 48.2 | 96.8 | 64.4 | 59.4 | 54.0 | ||||
| Interest expenses, bln rub | 0.000 | 0.001 | 0.000 | 3.91 | 0.000 | 0.686 | ||||
| Assets, bln rub | 158.3 | 329.7 | 247.7 | 156.3 | 158.6 | 137.9 | ||||
| Net Assets, bln rub | ? | -51.0 | -118.2 | -243.8 | -335.0 | 116.7 | 97.4 | |||
| Debt, bln rub | 200.6 | 8.74 | 28.5 | 28.1 | 25.3 | 19.7 | ||||
| Cash, bln rub | 154.7 | 315.1 | 209.8 | 122.8 | 131.4 | 112.7 | ||||
| Net debt, bln rub | 45.9 | -306.3 | -181.3 | -94.7 | -106.1 | -93.0 | ||||
| Ordinary share price, rub | 32.1 | 5.33 | 1.80 | 2.81 | 1.80 | |||||
| Number of ordinary shares, mln | 35.9 | 32.9 | 36.2 | 36.3 | 44.0 | 56.5 | ||||
| Market cap, bln rub | 0 | 1 055 | 193 | 65 | 124 | 102 | ||||
| EV, bln rub | ? | 46 | 748 | 12 | -29 | 17 | 9 | |||
| Book value, bln rub | -51 | -118 | -244 | -335 | 117 | 97 | ||||
| EPS, rub | ? | -1.15 | -1.99 | -3.40 | -2.33 | -1.88 | -1.29 | |||
| FCF/share, rub | -0.69 | -1.59 | -2.84 | -2.35 | -1.52 | -0.82 | ||||
| BV/share, rub | -1.42 | -3.59 | -6.74 | -9.22 | 2.66 | 1.72 | ||||
| EBITDA margin, % | ? | -1 603% | ||||||||
| Net margin, % | ? | -1 494% | ||||||||
| FCF yield, % | ? | -4.96% | -53.3% | -130.4% | -54.0% | -45.7% | ||||
| ROE, % | ? | 80.7% | 55.4% | 50.5% | 25.2% | -70.6% | -75.0% | |||
| ROA, % | ? | -26.0% | -19.9% | -49.7% | -54.1% | -52.0% | -53.0% | |||
| P/E | ? | 0.00 | -16.1 | -1.57 | -0.77 | -1.50 | -1.39 | |||
| P/FCF | 0.00 | -20.2 | -1.88 | -0.77 | -1.85 | -2.19 | ||||
| P/S | ? | 20.8 | ||||||||
| P/BV | ? | 0.00 | -8.92 | -0.79 | -0.20 | 1.06 | 1.04 | |||
| EV/EBITDA | ? | -1.57 | -11.2 | -0.09 | 0.32 | -0.20 | -0.11 | |||
| Debt/EBITDA | -1.57 | 4.60 | 1.43 | 1.03 | 1.23 | 1.19 | ||||
| R&D/CAPEX, % | 103 586% | 33 950% | 3 573% | 33 561% | 179 848% | 183.3% | ||||
| CAPEX/Revenue, % | 602.5% | |||||||||
| Black Diamond Therapeutics shareholders | ||||||||||
